» Articles » PMID: 38854617

Prader-Willi Syndrome: The More We Know, the Less We Know

Overview
Journal Mo Med
Specialty General Medicine
Date 2024 Jun 10
PMID 38854617
Authors
Affiliations
Soon will be listed here.
Abstract

Prader-Willi syndrome (PWS) is a complex genetic neurodevelopmental disorder with multisystem impact and a unique behavior profile that evolves over the life span. Beyond the primary care needs of all children and adults, the unique medical concerns and management needs of those with PWS are best served in a multidisciplinary academic center. Our PWS center has provided care for individuals with PWS and their families since 1981. Our growth hormone studies contributed to growth hormone supplementation becoming standard of care in this country. Here, in collaboration with the primary care provider, early childhood intervention programs, schools and local parent organizations, solid, patient-centered care for affected individuals and their families can be provided across the life-span. The purpose of this article is to provide a brief overview of PWS and the attendant medical and behavior management challenges attendant to the disorder.

Citing Articles

An Update on Advances in Hypopituitarism: Etiology, Diagnosis, and Current Management.

Iglesias P J Clin Med. 2024; 13(20).

PMID: 39458112 PMC: 11508259. DOI: 10.3390/jcm13206161.

References
1.
Whitman B, Carrel A, Bekx T, Weber C, Allen D, Myers S . Growth hormone improves body composition and motor development in infants with Prader-Willi syndrome after six months. J Pediatr Endocrinol Metab. 2004; 17(4):591-600. DOI: 10.1515/jpem.2004.17.4.591. View

2.
Hodapp R, Dykens E, Masino L . Families of children with Prader-Willi syndrome: stress-support and relations to child characteristics. J Autism Dev Disord. 1997; 27(1):11-24. DOI: 10.1023/a:1025865004299. View

3.
Muscogiuri G, Barrea L, Faggiano F, Maiorino M, Parrillo M, Pugliese G . Obesity in Prader-Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches. J Endocrinol Invest. 2021; 44(10):2057-2070. PMC: 8421305. DOI: 10.1007/s40618-021-01574-9. View

4.
Myers S, Whitman B, Carrel A, Moerchen V, Bekx M, Allen D . Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits. Am J Med Genet A. 2006; 143A(5):443-8. DOI: 10.1002/ajmg.a.31468. View

5.
Barrea L, Vetrani C, Fintini D, de Alteriis G, Panfili F, Bocchini S . Prader-Willi Syndrome in Adults: An Update On Nutritional Treatment and Pharmacological Approach. Curr Obes Rep. 2022; 11(4):263-276. PMC: 9729321. DOI: 10.1007/s13679-022-00478-w. View